Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
14-17 October, 2024
The MedTech ConferenceThe MedTech Conference
Not Confirmed
Not Confirmed
15-17 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
14-17 October, 2024
The MedTech ConferenceThe MedTech Conference
Industry Trade Show
Not Confirmed
15-17 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-have-built-considerable-expertise-in-glp-1-drug-development-through-our-oral-peptide-programs
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
07 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/serviers-voranigo-vorasidenib-tablets-receives-fda-approval-as-first-targeted-therapy-for-grade-2-idh-mutant-glioma-302215991.html
30 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/servier-initiates-critical-dialogue-on-aya-cancer-survivorship-at-asco-2024-302158733.html
23 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/servier-highlights-commitment-to-improving-cancer-outcomes-at-asco-2024-302153468.html
14 May 2024
// Nick Paul Taylor FIERCE PHARMA
https://www.fiercepharma.com/marketing/et-voila-new-name-takes-top-spot-reputation-ranking-us-patient-groups
14 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/servier-ranks-1st-across-several-categories-in-2023-2024-patientview-us-corporate-reputation-survey-302144762.html
18 Apr 2024
// 20MINUTES
https://www.20minutes.fr/economie/4087038-20240418-biogaran-poids-lourd-francais-medicaments-generiques-vendu-groupe-etranger
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8577
Submission : 1990-05-21
Status : Inactive
Type : II
Certificate Number : R1-CEP 2002-244 - Rev 03
Issue Date : 2020-05-14
Type : Chemical
Substance Number : 1108
Status : Valid
Registration Number : 217MF10330
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2005-08-09
Latest Date of Registration :
Registrant Name : Youngjin Pharmaceutical Co., Ltd.
Registration Date : 2021-05-18
Registration Number : 20210405-209-J-922(1)
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9171
Submission : 1991-06-10
Status : Inactive
Type : II
Certificate Number : R1-CEP 2004-223 - Rev 01
Issue Date : 2021-06-08
Type : Chemical
Substance Number : 2019
Status : Valid
Registration Number : 217MF10333
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2005-08-09
Latest Date of Registration :
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2022-01-03
Registration Number : 20220103-209-J-1190
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2005-182 - Rev 01
Issue Date : 2020-02-28
Type : Chemical
Substance Number : 1524
Status : Valid
Registration Number : 217MF10332
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2005-08-09
Latest Date of Registration :
Registrant Name : SK Chemical Co., Ltd.
Registration Date : 2011-08-12
Registration Number : 20050831-1-C-1-01(1)
Manufacturer Name : ORIL INDUSTRIES
Manufacturer Address : Plaine de Baclair, BOLBEC, 76210, France
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27979
Submission : 2014-03-14
Status : Active
Type : II
Registration Number : 230MF10037
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2018-02-26
Latest Date of Registration :
NDC Package Code : 75852-816
Start Marketing Date : 2014-02-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2009-05-28
Registration Number : 674-1-ND
Manufacturer Name : ORIL INDUSTIRE
Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27981
Submission : 2014-03-14
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27980
Submission : 2014-03-14
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27822
Submission : 2014-01-21
Status : Active
Type : II
NDC Package Code : 75852-817
Start Marketing Date : 2010-09-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2023-05-04
Registration Number : 20230504-211-J-1487
Manufacturer Name : ORIL Industrie (Site de Bolbec)
Manufacturer Address : 13, rue Auguste Desgenétais, BOLBEC, 76210, France
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : CEP 2024-029 - Rev 00
Issue Date : 2024-06-17
Type : Chemical
Substance Number : 2019
Status : Valid
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2022-01-03
Registration Number : 20220103-209-J-1190
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2015-244 - Rev 00
Issue Date : 2021-10-29
Type : Chemical
Substance Number : 2020
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Registration Number : 222MF10081
Registrant's Address : 13, rue Auguste Desgene(\') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2010-03-09
Latest Date of Registration :
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2021-03-16
Registration Number : 20210316-209-J-878
Manufacturer Name : ORIL Industrie (Site de Baclair)
Manufacturer Address : Plaine de Baclair – 76210 BOLBEC, France
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27980
Submission : 2014-03-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27981
Submission : 2014-03-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10106
Submission : 1993-02-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8577
Submission : 1990-05-21
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27979
Submission : 2014-03-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27822
Submission : 2014-01-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9171
Submission : 1991-06-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8576
Submission : 1990-05-21
Status : Inactive
Type : II
CEP/COS
Certificate Numbers : R1-CEP 2005-182 - Rev 01
Status : Valid
Issue Date : 2020-02-28
Type : Chemical
Substance Number : 1524
CEP/COS
Certificate Numbers : R0-CEP 2002-247 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2004-12-03
Type : Chemical
Substance Number : 1108
CEP/COS
Certificate Numbers : R1-CEP 2002-244 - Rev 03
Status : Valid
Issue Date : 2020-05-14
Type : Chemical
Substance Number : 1108
CEP/COS
Certificate Numbers : R1-CEP 2004-223 - Rev 01
Status : Valid
Issue Date : 2021-06-08
Type : Chemical
Substance Number : 2019
Certificate Numbers : CEP 2024-029 - Rev 00
Status : Valid
Issue Date : 2024-06-17
Type : Chemical
Substance Number : 2019
CEP/COS
Certificate Numbers : R1-CEP 2015-244 - Rev 00
Status : Valid
Issue Date : 2021-10-29
Type : Chemical
Substance Number : 2020
JDMF
Registration Number : 217MF10332
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2005-08-09
Latest Date of Registration : 2018-04-09
JDMF
Registration Number : 217MF10330
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2005-08-09
Latest Date of Registration : 2021-02-16
JDMF
Registration Number : 230MF10037
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2018-02-26
Latest Date of Registration : 2018-02-26
JDMF
Registration Number : 217MF10333
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2005-08-09
Latest Date of Registration : 2008-11-21
Registration Number : 222MF10081
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2010-03-09
Latest Date of Registration : 2010-03-09
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2010-05-27
Registration Number : Su3056-1-ND
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France
Registrant Name : SK Chemical Co., Ltd.
Registration Date : 2011-08-12
Registration Number : 20050831-1-C-1-01(1)
Manufacturer Name : ORIL INDUSTRIES
Manufacturer Address : Plaine de Baclair, BOLBEC, 76210, France
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-1-C-1-01
Manufacturer Name : ORIL INDUSTRIES
Manufacturer Address : Plaine de Baclair, BOLBEC, 76210, France
Registrant Name : Youngjin Pharmaceutical Co., Ltd.
Registration Date : 2021-05-18
Registration Number : 20210405-209-J-922(1)
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2021-04-05
Registration Number : 20210405-209-J-922
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2009-05-28
Registration Number : 674-1-ND
Manufacturer Name : ORIL INDUSTIRE
Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2023-05-04
Registration Number : 20230504-211-J-1487
Manufacturer Name : ORIL Industrie (Site de Bolbec...
Manufacturer Address : 13, rue Auguste Desgenétais, BOLBEC, 76210, France
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2022-01-03
Registration Number : 20220103-209-J-1190
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2021-03-16
Registration Number : 20210316-209-J-878
Manufacturer Name : ORIL Industrie (Site de Baclai...
Manufacturer Address : Plaine de Baclair – 76210 BOLBEC, France
NDC Package Code : 75852-816
Start Marketing Date : 2014-02-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 75852-817
Start Marketing Date : 2010-09-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Details:
Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: Voranigo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier’s VORANIGO® Receives FDA Approval as First Targeted Therapy for IDH Glioma
Details : Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma.
Brand Name : Voranigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Details:
AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: AG-881
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA and EMA Accept Vorasidenib Submissions for IDH-Mutant Glioma
Details : AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for IDH-mutant diffuse glioma.
Brand Name : AG-881
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2024
Details:
The agreement aims to develop RNA-targeted small molecule therapeutics by leveraging Base4's platform to identify RNA-modulating compounds for neuroscience research.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Small molecule
Recipient: Base4 Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Recipient : Base4 Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development
Details : The agreement aims to develop RNA-targeted small molecule therapeutics by leveraging Base4's platform to identify RNA-modulating compounds for neuroscience research.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2024
Details:
AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: AG-881
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Brand Name : AG-881
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2023
Details:
Tibsovo (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated...
Details : Tibsovo (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2023
Details:
TIBSOVO® (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in ...
Details : TIBSOVO® (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2023
Details:
Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Aitia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2023
Details : Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2023
Details:
Tibsovo® (ivosidenib tablets) is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Receives European Commission Approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Ac...
Details : Tibsovo® (ivosidenib tablets) is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 10, 2023
Details:
AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: AG-881
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Brand Name : AG-881
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2023
Details:
Tibsovo (ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Receives a Positive CHMP Opinion For Tibsovo® in IDH1-Mutated Acute Myeloid Leukemia (AML...
Details : Tibsovo (ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leu...
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2023
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Brand Name : Agomelatine Servier
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtabl
Brand Name : Valdoxan
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtabl
Brand Name : Valdoxan
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Brand Name : Agomelatine Servier
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : Prescription
Registration Country : Canada
AMLODIPINE (AMLODIPINE BESYLATE)
Dosage Form : TABLET
Brand Name : VIACORAM
Dosage Strength : 10MG
Packaging : 30
Approval Date :
Application Number : 2451557
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
AMLODIPINE (AMLODIPINE BESYLATE)
Dosage Form : TABLET
Brand Name : VIACORAM
Dosage Strength : 5MG
Packaging : 30/100
Approval Date :
Application Number : 2451549
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
AMLODIPINE (AMLODIPINE BESYLATE)
Dosage Form : TABLET
Brand Name : VIACORAM
Dosage Strength : 2.5MG
Packaging : 30/100
Approval Date :
Application Number : 2451530
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Switzerland
Atorvastatinum; Perindoprilum argininum; Amlodipinum
Dosage Form : Filmtabl
Brand Name : Triveram
Dosage Strength : 40/10/10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Atorvastatinum; Perindoprilum argininum; Amlodipinum
Dosage Form : Filmtabl
Brand Name : Triveram
Dosage Strength : 10/5/5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Atorvastatinum; Perindoprilum argininum; Amlodipinum
Dosage Form : Filmtabl
Brand Name : Triveram
Dosage Strength : 20/10/10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Services
Packaging
API Manufacturing
Drug Product Manufacturing
Analytical
API & Drug Product Development
Inspections and registrations
ABOUT THIS PAGE
Servier is a supplier offers 13 products (APIs, Excipients or Intermediates).
Find a price of Indapamide bulk with CEP, JDMF offered by Servier
Find a price of Perindopril Erbumine bulk with CEP, JDMF offered by Servier
Find a price of Gliclazide bulk with CEP, JDMF offered by Servier
Find a price of Ivabradine Hydrochloride bulk with DMF, JDMF offered by Servier
Find a price of Captopril bulk with DMF offered by Servier
Find a price of Hexahydroazepine bulk with DMF offered by Servier
Find a price of Perindopril Arginine bulk with DMF offered by Servier
Find a price of Perindopril Erbumine bulk with CEP offered by Servier
Find a price of Rilmenidine Phosphate bulk with CEP offered by Servier
Find a price of Trimetazidine bulk with JDMF offered by Servier
Find a price of Dexfenfluramine bulk offered by Servier
Find a price of Indapamide bulk offered by Servier
Find a price of FACILITIES AND OPERATING PROCEDURES IN BOLBEC, FRANCE bulk offered by Servier
LOOKING FOR A SUPPLIER?